Results 191 to 200 of about 6,057,330 (258)

Diagnostic and therapeutic impact of implantable cardiac monitors across different clinical indications: a real-world cohort. [PDF]

Eur Heart J Open
Castro M, Calvo L, Pinheiro L, Tinoco M, Garcia BL, Paredes AC, Alves A, Rodrigues B, Português J, Ribeiro S, Sanfins V, Lourenço A.   +11 more
europepmc   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

International survey in four European countries on diagnostic reference levels based on clinical indications in computed tomography. [PDF]

Insights Imaging
Schegerer AA, Jungnickel K, Walz M, Verius M, Singer J, Renger B, Oberhofer N, Müller C, Menz R, Madsack B, Fiebich M, Eßeling R, Borowski M, Bazrafshan B, Ammon J, Aberle C, Stamm G.   +16 more
europepmc   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Pediatric dental treatment under general anesthesia: a retrospective analysis of clinical indications and a survey of pediatric dentist referral practices. [PDF]

Front Dent Med
Fux-Noy A, Raz M, Masrawa K, Shmueli A, Halperson E, Moskovitz M.   +5 more
europepmc   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Expanding the Role of Implantable Loop Recorders: Diagnostic and Therapeutic Yields Across Seven Clinical Indications in 388 Real-World Patients. [PDF]

J Clin Med
Plappert C, Lacour P, Parwani AS, Boldt LH, Bähr F, Schöppenthau D, Feuerstein A, Wieland LH, Heil E, Hohendanner F, Dagres N, Hindricks G, Hilgendorf I, Blaschke F.   +13 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Failure patterns and clinical indications in early-stage follicular lymphoma: a study from the National Cancer Center in China. [PDF]

Front Pharmacol
Xu C, Yang S, Liu Y, Wu Y, Liu X, Zhong QZ, Yang Y, Wu T, Chen SY, Chen B, Song YW, Fang H, Jin J, Liu YP, Jing H, Tang Y, Li N, Lu NN, Zhang WW, Wang SL, Zhu J, Qi SN, Li YX.   +22 more
europepmc   +1 more source